AUG 19, 2019 9:36 AM PDT

FDA Approves New Treatment for Extensively Drug-Resistant TB

WRITTEN BY: Tiffany Dazet

Last week, the U.S. Food and Drug Administration (FDA) approved a new treatment for a severe form of multi-drug-resistant tuberculosis of the lungs. According to a press release from the FDA, the treatment consists of a six-month regimen of pretomanid tablets combined with bedaquiline and linezolid—referred to as the BPaL regimen. This is one of three tuberculosis treatments to gain FDA approval in the past 40 years. During clinical trials, about 90% of participants using this treatment recovered within six months.

It’s estimated that 1.6 million people die from tuberculosis every year, killing more than any other infectious disease. An article in Nature states that half a million people worldwide are diagnosed with multi-drug-resistant tuberculosis every year. Of those, 8.5% have XDR TB—extensively drug-resistant tuberculosis—which according to RTI, is resistant to four of the main tuberculosis treatments currently in use worldwide. Mel Spigelman, president of the TB Alliance, told Nature “drug-resistant TB is the largest single source of antimicrobial resistance in the world.”

Pretomanid was developed by RTI International as part of the TB Alliance, which is a non-profit product development partnership established in 2000. The team was led by Dr. Doris Rouse, as RTI International scientist. In a statement from RTI, Dr. Rouse said “I’ve been in wards with patients that are so emaciated, they won’t eat anything, they have fevers, they can’t sleep. But with pretomanid, in a regimen that contains two other drugs, bedaquiline and linezolid, we see improvement within a few weeks.”

The development of pretomanid took nearly 20 years. Dr. Rouse commented, “We’ve worked on this new drug for 19 years and it hasn’t always been an easy path. But as I’ve always said, ‘One of the main ingredients for successful drug development is blessed stubbornness.’”

Affordable pricing will be a major hurdle to make the treatment accessible to impoverished patients. According to Sharonann Lynch, the TB advisor for Doctors Without Borders, only 20% of those who needed bedaquiline were able to afford it. Nature states that a six-month supply of bedaquiline and delaminid can cost hundreds to thousands of dollars. The price of the new treatment is currently under negotiations by the TB Alliance.

Sources: FDA, RTI, Nature
 

About the Author
  • Tiffany grew up in Southern California, where she attended San Diego State University. She graduated with a degree in Biology with a marine emphasis, thanks to her love of the ocean and wildlife. With 13 years of science writing under her belt, she now works as a freelance writer in the Pacific Northwest.
You May Also Like
OCT 01, 2020
Chemistry & Physics
Canadian Scientists Hope to Take Lead in Neutron Research, Again
OCT 01, 2020
Canadian Scientists Hope to Take Lead in Neutron Research, Again
(Pixabay/geralt) Neutron sources are the key to advancing research in many areas such as energy storage, mechanical engi ...
OCT 05, 2020
Cancer
Does Having an Appendectomy Increase Your Risk for Cancer?
OCT 05, 2020
Does Having an Appendectomy Increase Your Risk for Cancer?
Cancer research is more than just the study of diagnostics and novel therapies. Researchers also investigate the causes ...
OCT 07, 2020
Genetics & Genomics
Researchers Confirm Cerebral Palsy Has a Genetic Component
OCT 07, 2020
Researchers Confirm Cerebral Palsy Has a Genetic Component
Scientists have confirmed previous studies that have suggested that some cases of cerebral palsy are due to a genetic mu ...
OCT 14, 2020
Immunology
Happiness Linked to Heart Attack Risk
OCT 14, 2020
Happiness Linked to Heart Attack Risk
Asking patients questions about their personal lives could predict their future risk of a heart attack. A study, publish ...
OCT 14, 2020
Chemistry & Physics
The CRISPR Nobel Win from Different Angles
OCT 14, 2020
The CRISPR Nobel Win from Different Angles
CRISPR-Cas9 was THE buzz word in the world of science after the Nobel Chemistry Prize announcement last week. But depend ...
OCT 21, 2020
Drug Discovery & Development
New ALS Treatment Extends Life for Several Months
OCT 21, 2020
New ALS Treatment Extends Life for Several Months
Currently, there are only two approved medications to treat Lou Gehrig's disease (also known as ALS), a condition po ...
Loading Comments...